SIETES :: 92261 citas

Resultados de la búsqueda por OSTEOPOROSIS REFINAR BÚSQUEDA

1.

Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open 2018;8:e019759. [Ref.ID 102510]

2.

Zhao J-G, Zeng X-T, Wang J, Liu L. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults. A systematic review and meta-analysis. JAMA 2017;318:2466-82. [Ref.ID 102195]

3.

McNeil M. Menopausal hormone therapy. Understanding long-term risks and benefits. JAMA 2017;318:911-3. [Ref.ID 102069]

4.

Sugiyama T. Osteoporotic fractures associated with dabigatran vs warfarin. JAMA 2017;318:90-1. [Ref.ID 102054]

5.

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorenzton M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017:11 de septiembre. [Ref.ID 102052]

6.

Anónimo. Diphosphonates: valvulopathies?. Prescrire 2017;37:511-2. [Ref.ID 102010]

7.

de Boissieu P, Kanagaratnam L, Mahmoudi R, Morel A, Dramé M, Trenque T. Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol 2017;73:517-23. [Ref.ID 101992]

8.

Anónimo. Strontium ranelate discontinued. Prescribing Advice for GPs 2017:1. [Ref.ID 101637]

9.

Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 2016;20:1-406. [Ref.ID 101044]

10.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016;375:1532-43. [Ref.ID 100908]

11.

Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo A, Alexandersen P, Zerbini CAF, Hu M-y, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, for the ACTIVE Study Investigators. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 2016;316:722-33. [Ref.ID 100710]

12.

Cappola AR, Shoback DM. Osteoporosis therapy in postmenopausal women with high risk of fracture. JAMA 2016;316:715-6. [Ref.ID 100709]

13.

Kern J, Kern S, Blennow K, Zetterberg H, Waern M, Guo X, Börjesson-Hanson A, Skoog I, Östling S. Calcium supplementation and risk of dementia in women with cerebrovascular disease. Neurology 2016:17 de agosto. [Ref.ID 100583]

14.

Rousseau C, Jean S, Garnache P, Lebel S, Mac-Way F, Biertho L, Michou L, Gagnon C. Change in fracture risk and fracture pattern after bariatric surgery: nested case-control study. BMJ 2016;354:i3794. [Ref.ID 100518]

15.

Paskins Z, Warburton L. Bisphosphonates beyond five years. BMJ 2016;352:i264. [Ref.ID 100306]

16.

Yeh MW, Zhou H, Adams AL, Ituarte PHG, Liu IA, Haigh PI. The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism: an observational study. Ann Intern Med 2016:5 de abril. [Ref.ID 100114]

17.

Moro Álvarez MJ, Neyro JL, Castañeda S. Vacaciones terapéuticas en osteoporosis: estrategia en el tratamiento a largo plazo con bifosfonatos. Med Clin (Barc) 2016;146:24-9. [Ref.ID 99986]

18.

Rubin R. GAO reports costs of new Medicare Part B drugs in 2013. JAMA 2016;315:122. [Ref.ID 99972]

19.

Anónimo. Prevención de fracturas osteoporóticas y duración del tratamiento. Boletín Terapéutico Andaluz 2015;30:1. [Ref.ID 99827]

20.

Anónimo. Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal. Drug Safety Update 2015;9:4. [Ref.ID 99748]